Ninth Circuit Ruling on Preemption Defense Introduces New Legal Risk to UnitedHealth's Medicare Advantage Turnaround

What happened

The Ninth Circuit Court of Appeals is reviewing a case that could strip UnitedHealth of a key preemption defense, potentially exposing it to greater liability in Medicare Advantage fraud lawsuits. This legal uncertainty emerges as UNH is executing a delicate operational reset, guided by improving its Medical Care Ratio (MCR) to 88.8% ±50 bps amid CMS policy tightening by early April 2026. The DeepValue report frames UNH's investment case as a 'potential buy' contingent on this MCR improvement and favorable CMS outcomes, but underplays specific legal exposures like this preemption challenge. A loss in court would heighten regulatory scrutiny and fraud risks, compounding pressures from CMS's proposed risk-adjustment cuts and already elevated medical costs. For investors, this adds a non-operational wildcard that could delay or derail the earnings recovery narrative central to the stock's upside.

Implication

If the preemption defense fails, UNH could face a surge in fraud litigation, leading to potential financial settlements and reputational damage that strain margins. This aligns with the broader regulatory headwinds highlighted in the DeepValue report, such as CMS's -3.32%/-1.53% risk-adjustment cuts, which already pressure Medicare Advantage profitability. Operationally, heightened legal scrutiny may force UNH to divert resources to compliance, undermining its guided MCR improvement and 'right-sizing' efforts. Financially, adverse rulings could trigger reserve increases or impact cash flows, challenging the company's aggressive capital return plan of $8B dividends and $2.5B buybacks. Ultimately, this introduces a persistent legal risk that could erode investor confidence and amplify the bear case if operational execution falters.

Thesis delta

The investment thesis remains anchored on UNH delivering MCR improvement and navigating CMS policy, but the Ninth Circuit case adds a material downside risk not fully priced in the DeepValue report. A loss of preemption would tighten the regulatory noose, potentially accelerating margin pressures and legal costs beyond current bear scenarios. This shifts the risk-reward balance slightly negative, requiring investors to monitor legal outcomes as critically as operational metrics over the next 3-6 months.